Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IDEXX Laboratories

LHC Group

Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.

3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings

DaVita

Owens & Minor

Grab these four stocks that continue to show tremendous promise despite market volatility resulting from the coronavirus pandemic.

4 MedTech Stocks to Enrich Your Portfolio Ahead of Q3 Earnings

Novocure

Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.

3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2021 on Thursday, October 29, 2020, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this call. Earnings webcast details: • Location: http://investor.resmed.com • Date: Thursday,

ResMed to Report First Quarter Fiscal 2021 Earnings on October 29, 2020

Domino's Pizza

Meritage Homes

NRG Energy

Vertex Pharmaceuticals

Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.

Add These 5 Stocks With Impressive Interest Coverage Ratio

AmerisourceBergen

Chemed

Neogen

Novo Nordisk

As the world grapples with an unprecedented coronavirus pandemic, five health care stocks that have outperformed the Standard & Poor's 500 Index by at least 5% in the year to date are AmerisourceBergen Corp. (NYSE:ABC), Chemed Corp. (NYSE:CHE), Neogen Corp. (NASDAQ:NEOG), Novo Nordisk A/S (NYSE:NVO) and ResMed Inc. (NYSE:RMD) according to the All-in-One Screener, a Premium feature of GuruFocus.

5 Health Care Stocks Outperforming the S&P 500

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on Monday, September 14, 2020, beginning at approximately 12:45 p.m. (Eastern Daylight Time) via video webcast.

ResMed Announces Participation in the Morgan Stanley 18th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- The MIT Leaders for Global Operations (LGO) program announced today that ResMed, a global digital health and connected medical device company, has become the newest member of its industry partnership.

MIT Leaders for Global Operations announces new industry partnership with ResMed

ResMed (RMD) reported earnings 30 days ago. What's next for the stock?

Why Is ResMed (RMD) Up 1.3% Since Last Earnings Report?

Many people consider themselves either value investors or growth investors. Here's why that mindset can blind them to some of the best opportunities.

Why ResMed Investors Can Sleep Well at Night

ResMed (RMD) adds another product to its line of easy-to-use, convenient and comfortable masks.

ResMed (RMD) Launches First CPAP Nasal Mask With Memory Foam

SAN DIEGO--(BUSINESS WIRE)---- $RMD #CPAP--ResMed’s first nasal memory foam cushion enhances patients’ comfort and convenience, doesn’t need cleaning when replaced on an appropriate schedule.

ResMed Debuts AirTouch N20 Foam CPAP Mask, Its Softest Nasal Mask Ever

A Relative Strength Rating upgrade for Resmed shows improving technical performance. Will it continue?

IBD Rating Upgrades: Resmed Flashes Improved Relative Price Strength

ResMed's (RMD) top line reflects strong segmental and geographic performance boosted by pandemic-led demand growth for ventilators.

ResMed (RMD) Q4 Earnings & Revenues Top Estimates, Margins Up

The healthcare company got some help from the COVID-19 pandemic.

How ResMed Trounced Expectations in Q4

ResMed, Inc. (RMD) CEO Mick Farrell on Q4 2020 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 37.11% and 8.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q4 Earnings and Revenues Surpass Estimates

SAN DIEGO--(BUSINESS WIRE)--ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended June 30, 2020.

ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2020

Camping World Hlds

Fiserv

Fastly

Global Blood Therapeutics

Medifast

Cimarex Energy

Seven top-ranked companies are poised to beat on earnings today after the closing bell.

Top 7 Stocks Set to Beat on Earnings Today After Market

Health Catalyst Inc

Transmedics Group Inc

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

3 Medical Product Stocks Set to Beat This Earnings Season

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can ResMed (RMD) Keep the Earnings Surprise Streak Alive?

Is  (RMD) Outperforming Other Medical Stocks This Year?

Has ResMed (RMD) Outpaced Other Medical Stocks This Year?

Patterson Companies

West Pharmaceutical Services

Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.

3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ResMed (RMD) Hits 52-Week High, Can the Run Continue?

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2020 on Wednesday, August 5, 2020, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results.

News for ResMed Stock (RMD)